Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?
Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.
Sinorda bets on bispecifics with WuXi Biologics for IBD and autoimmune expansion
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006, […]
Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.
Sixty Degrees Pharmaceuticals bets on purification science to unlock castanospermine commercialization
Find out how Sixty Degrees Pharmaceuticals is repositioning castanospermine through a botanical pathway and what regulatory and manufacturing risks still remain.
Johnson & Johnson expands DARZALEX FASPRO label with new D-VRd approval in newly diagnosed myeloma
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.
Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Will TETRAPHARM’s TPC-026 unlock the chronic-care gap in metabolic disorders?
Can TPC-026 fill the gap after GLP-1s? Find out how TETRAPHARM’s novel compound could reshape long-term metabolic care.
What sets Hanmi’s GLP-1 strategy apart as efpeglenatide heads into Latin America
Hanmi taps Sanfer to launch GLP-1 drug efpeglenatide in Mexico. Find out what this deal reveals about Latin America’s obesity drug market strategy.
Is Skyhawk’s SKY-0515 the first disease-modifying breakthrough in Huntington’s disease?
Skyhawk’s SKY-0515 shows functional gains in Huntington’s disease. Find out how RNA modulation could alter the treatment landscape.